SL Science Holding Limited fell 18.9% on Thursday, November 5, 2026, on 139,562 shares, 2.1 times its average daily volume. No headline about SLBT came out that day or the day before in the news feeds we follow, so the move may come from news we don't track, the sector or trading alone.
SL Science Holding Limited (SLBT:NASDAQ) closed at $0.938 on November 6, 2026, up 4.16% on the day. The stock trades 93.5% below its 52-week high of $14.50 and 26.7% above its 52-week low of $0.740. Over the past year, it lost 91.1%. SL Science Holding Limited is part of the Health Care sector.
In 220 trading sessions since December 23, 2025, SLBT closed higher on 77 days (35%). Its best day was June 16, 2026 (+166.97%) and its worst was June 12, 2026 (-47.37%). The stock moved 10% or more in a single session 35 times. It opened at least 5% above the previous day's high 8 times.
Early-stage biotechnology holding company advancing scalable cell-therapy platforms for global immune-based medicine. In the global oncology market, cell therapy is widely recognized as one of the most transformative approaches in modern medicine. Despite its clinical promise, however, the industry has yet to scale into a true global platform due to three core limitations: lack of standardization, limited manufacturing capacity, and extremely high costs. By comparison, some of the world's most successful global industries-such as semiconductors-achieved scale not through technology alone, but through standardized processes, mass production, and globally scalable manufacturing systems. SLBT Group GDT platform is designed to apply this same industrial logic to cell therapy. The platform aims to transform cell therapy from a highly customized medical procedure into a platform-based, modular, scalable, and reproducible business model.
Find more stocks like SLBT with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.